Pasithea Therapeutics Corp. (KTTAW) 株式分析

企業概要

Pasithea Therapeutics Corp. is a clinical-stage biotechnology enterprise dedicated to the discovery, research, and development of therapeutic interventions for central nervous system disorders, RASopathies, and various forms of cancer. The company operates within the biotechnology sector, focusing specifically on the pharmaceutical industry where innovation in drug discovery is paramount for addressing complex medical conditions. As of the latest available data, the company's market capitalization is listed as unavailable (N/A), its annual revenue is not disclosed (N/A), and it employs a workforce of five individuals. These figures, combined with a reported price-to-book ratio of 0.00, indicate that the company is an early-stage biotech entity with no positive earnings or established sales volume to support a traditional market valuation, reflecting its position as a high-risk, high-potential venture reliant on future clinical trial success rather than current operational cash flow.

財務健全性

The company reports a net income of $-20,427,684 over the trailing twelve months, with an EBITDA of $-16,031,099, while revenue is not available (N/A). The substantial gap between the negative net income and the less negative EBITDA suggests that non-operating expenses, likely related to stock-based compensation or interest income on cash holdings, are significantly impacting the bottom line. Free cash flow stands at $-6,473,837, indicating that the company is consuming cash to fund its research and development activities, which is typical for clinical-stage firms but limits immediate financial flexibility without external capital raises. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting the lack of positive revenue streams against which to calculate profitability ratios at this stage of development. The balance sheet shows a cash position of $55.16M contrasted with zero debt, resulting in a debt-to-equity ratio that is effectively non-existent or N/A, suggesting a highly conservative and unleveraged capital structure. Furthermore, the current ratio is 11.35, which signals an exceptionally strong short-term liquidity position capable of covering current liabilities many times over. However, the return on equity is -58.4% and the return on assets is -27.3%, metrics that reveal management is currently burning capital to achieve clinical milestones rather than generating shareholder returns or asset appreciation.

バリュエーション評価

The trailing P/E ratio and forward P/E ratio are both listed as unavailable (N/A), as the company has not yet achieved positive earnings to support these traditional valuation multiples. The price-to-book ratio is 0.00, which indicates that the company's market valuation is effectively zero relative to its book value, a common characteristic for pre-revenue biotech firms where assets are often intangible or future-oriented. Similarly, the price-to-sales ratio and EV/EBITDA multiple are unavailable (N/A), suggesting that alternative valuation metrics relying on revenue or earnings generation are not applicable at this point in the company's lifecycle. The stock has traded with a 52-week high of $0.01 and a 52-week low of $0.01, meaning the current trading price sits exactly at both the upper and lower bounds of this range with no price fluctuation observed during the year. The beta value is 0.25, which implies that the stock's price volatility is significantly lower than that of the broader market, likely due to low trading volume and a niche market capitalization rather than fundamental stability.

Growth & Income

The revenue growth year-over-year and earnings growth year-over-year are both unavailable (N/A), precluding any analysis of growth rates or the relationship between earnings expansion and top-line revenue expansion. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio to shareholders, instead choosing to reinvest all available capital into advancing its lead product candidate, PAS-004, through clinical development. This strategy prioritizes long-term asset growth and clinical trial progression over providing immediate income to investors. Consequently, the overall growth and income profile for Pasithea Therapeutics Corp. is characterized by a complete absence of current earnings growth, dividend income, or revenue expansion, relying entirely on the successful execution of its research pipeline to create future value.